Text Box: CLINICAL PRESENTATIONS AND TREATMENT OF CHILDHOOD B-CELL NON-HODGKIN'S LYMPHOMA IN A SINGLE MEDICAL CENTER Pan C, Tang JY, Wang YP, Chen J, Chen J, Xue HL, Zhao HJ, Gu LJ Department of Pediatric Hematology/Oncology, Shanghai Xinhua Hospital, Shanghai Children's Medical Center, China Objective: To highlight the diverse clinical presentations of childhood B-cell Non-Hodgkin's lymphoma, and to verify the efficacy of B-NHL-CCCG-97. Methods: From Jan 1st 1993 to June 30th 2000, 89 patients with childhood Non-Hodgkin's lymphoma were admitted to our hospital. Thirty-five were B-cell types (39.3%), and 33 received chemotherapy and were eligible for analysis. There were 16 male patients and 7 female (M/F=2.3:1). The median age was 7.4 years (range 2.5-17 years). Staging data revealed one patient with Stage I, 4 with Stage II, 15 with Stage III, and 13 with Stage IV disease. The initial sites were: neck mass/neck lymphadenopathy in 7 patients, nasopharyngeal mass in 6, abdominal masses in 15, bone lesion in 2, extra-meningeal mass in 1, back mass in 1, and parotid mass in 1. 33 patients received B-NHL-CCCG-97 Protocol (known as MCP-842 Protocol before 1997). Results: 30 patients (90.9%) achieved CR. The OS was 72.4%. Of the 3 patients (9.1%) who did not achieve remission, 1 was Stage III, Burkitt's morphology, with extensive intra-abdominal involvement. One patient at Stage IV whose primary site was nasopharynx with CNS involved, and another patient at Stage IV had extra-meningeal mass. 5 patients (15.2%) relapsed, 2 were Stage IV patients with both bone marrow and CNS involvement, 2 were Stage III patients with extensive intra-abdominal involvement, and 1 patient was Stage III with bone primary. The median time of the relapse was 4.2 months (range 1-6 months) after CR. The last patient achieved CR again and is in CR2 for 10 months. 5 patients (15.2%) died, 3 after relapse, and 2 died during induction chemotherapy due to infections. The median following up time was 34.7 months (range 4-86 months). 3 patients were lost to follow up, 1 after 3 courses of the treatment and did not receive CR, and 2 after CCR for 6 months. Conclusion: B-NHL-CCCG-97 is effective for treating patients with childhood B- cell Non-Hodgkin's lymphoma. 1858